Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;43(10):3587-3594.
doi: 10.1007/s10792-023-02765-4. Epub 2023 Jul 4.

Practical applications of vitreous imaging for the treatment of vitreous opacities with YAG vitreolysis

Shangjun Jiang  1 , John Golding  2 , Netan Choudhry  3
Affiliations

Practical applications of vitreous imaging for the treatment of vitreous opacities with YAG vitreolysis

Shangjun Jiang et al. Int Ophthalmol. 2023 Oct.

Abstract

Purpose: To demonstrate the methodology and efficacy of using scanning laser ophthalmoscopy (SLO) and dynamic optical coherence tomography (OCT) to identify and treat symptomatic vitreous floaters using yttrium-aluminum garnet laser vitreolysis (YLV).

Methods: This is a case series highlighted from a cross sectional retrospective study conducted at the Vitreous Retina Macula Specialists of Toronto. Forty eyes from thirty-five patients were treated with YLV between November 2018 and December 2020 for symptomatic floaters and imaged with SLO and dynamic OCT. Patients were re-treated with YLV if they reported ongoing significant vision symptoms during follow-up which correlated to visible opacities on exam and or imaging. Three cases will be highlighted to present the practical applications of SLO and dynamic OCT imaging for YLV treatment.

Results: Forty treated eyes were enrolled in this study, with twenty-six eyes (65%) requiring at least one repeat YLV treatment following the first treatment due to ongoing symptomatic floaters. Following the first YLV, there was a significant improvement in overall mean best corrected visual acuity compared to before treatment (0.11 ± 0.20 LogMAR units vs. 0.14 ± 0.20 LogMAR units, p = 0.02 (paired t test)). Case 1 demonstrates a dense, solitary vitreous opacity that has been localized with dynamic OCT imaging to track its movements and retinal shadowing with the patient's eye movements. Case 2 shows the utility of adjusting the fixation target to monitor the movement of vitreous opacities in real-time. Case 3 exhibits an association between decreased symptom burden and vitreous opacity density after YLV.

Conclusion: Image-guided YLV facilitates the localization and confirmation of vitreous opacities. SLO and dynamic OCT of the vitreous can provide a real-time evaluation of floater size, movement, and morphology, to help clinicians target treatment and monitoring of symptomatic floaters.

Keywords: Dynamic OCT; Floaters; OCT; Scanning laser ophthalmoscopy; Vitreolysis; YAG laser.

PubMed Disclaimer

References

    1. Luo J, An X, Kuang Y (2018) Efficacy and safety of yttrium-aluminium garnet (YAG) laser vitreolysis for vitreous floaters. J Int Med Res 46:4465–4471. https://doi.org/10.1177/0300060518794245 - DOI - PubMed - PMC
    1. Singh IP (2018) Novel OCT application and optimized YAG laser enable visualization and treatment of mid- to posterior vitreous floaters. Ophthal Surg Lasers Imaging Retin 49:806–811. https://doi.org/10.3928/23258160-20181002-10 - DOI
    1. Shah CP, Heier JS (2017) YAG laser vitreolysis vs sham YAG vitreolysis for symptomatic vitreous floaters. JAMA Ophthalmol 135:918. https://doi.org/10.1001/jamaophthalmol.2017.2388 - DOI - PubMed - PMC
    1. Sebag J, Yee KMP, Wa CA et al (2014) Vitrectomy for floaters: prospective efficacy analyses and retrospective safety profile. Retina 34:1062–1068. https://doi.org/10.1097/IAE.0000000000000065 - DOI - PubMed
    1. Zou H, Liu H, Xu X, Zhang X (2013) The impact of persistent visually disabling vitreous floaters on health status utility values. Qual Life Res 22:1507–1514. https://doi.org/10.1007/s11136-012-0256-x - DOI - PubMed